Editorial 新薬発売の失敗 2013年1月1日 Nature Biotechnology 31, 1 doi: 10.1038/nbt.2482 A slew of disappointing product launches suggests biotech companies are ill prepared to navigate an increasingly parsimonious reimbursement environment. Full text PDF 目次へ戻る
